PRXL2C

Summary

PRXL2C (peroxiredoxin like 2C, HGNC:16881) is a protein-coding gene on chromosome 9q22.33, encoding Peroxiredoxin-like 2C (Q7RTV5). May positively regulate ERK1/2 signaling and AKT1 activation leading to HIF1A up-regulation with an increased expression of glycolysis genes and enhanced glycolysis.

Involved in positive regulation of ERK1 and ERK2 cascade and positive regulation of glycolytic process.

Source: NCBI Gene 195827 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 33 total
• MANE Select transcript: NM_153698

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16881
Approved symbol	PRXL2C
Name	peroxiredoxin like 2C
Location	9q22.33
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000158122
Ensembl biotype	protein_coding
Entrez	195827

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 8 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000375234, ENST00000411939, ENST00000446045, ENST00000464512, ENST00000875712, ENST00000875713, ENST00000875714, ENST00000946150, ENST00000946151

RefSeq mRNA: 1 — MANE Select: NM_153698 NM_153698

CCDS: CCDS35073

Canonical transcript exons

ENST00000375234 — 6 exons

Exon	Start	End
ENSE00001037162	96654705	96654773
ENSE00001091594	96645893	96646024
ENSE00001627164	96639577	96641886
ENSE00001908433	96655090	96655317
ENSE00003476928	96651390	96651495
ENSE00003515573	96651659	96651712

Expression profiles

Bgee: expression breadth ubiquitous, 233 present calls, max score 91.35.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.3174 / max 109.2504, expressed in 1794 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
101603	16.3731	1794
101604	0.5388	317
101605	0.4054	189

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left ventricle myocardium	UBERON:0006566	91.35	gold quality
heart right ventricle	UBERON:0002080	91.13	gold quality
tibialis anterior	UBERON:0001385	89.25	silver quality
calcaneal tendon	UBERON:0003701	87.95	gold quality
saphenous vein	UBERON:0007318	87.08	gold quality
buccal mucosa cell	CL:0002336	85.75	silver quality
myocardium	UBERON:0002349	85.35	silver quality
bronchial epithelial cell	CL:0002328	84.97	gold quality
cartilage tissue	UBERON:0002418	84.97	gold quality
islet of Langerhans	UBERON:0000006	84.92	gold quality
mucosa of paranasal sinus	UBERON:0005030	84.65	gold quality
bronchus	UBERON:0002185	84.45	gold quality
cardiac ventricle	UBERON:0002082	84.20	gold quality
lower lobe of lung	UBERON:0008949	84.20	gold quality
heart left ventricle	UBERON:0002084	84.18	gold quality
decidua	UBERON:0002450	84.09	gold quality
subcutaneous adipose tissue	UBERON:0002190	83.67	gold quality
bone marrow cell	CL:0002092	83.51	gold quality
colonic epithelium	UBERON:0000397	83.41	gold quality
hindlimb stylopod muscle	UBERON:0004252	83.35	gold quality
mammary duct	UBERON:0001765	83.33	gold quality
epithelium of mammary gland	UBERON:0003244	83.27	gold quality
cardiac muscle of right atrium	UBERON:0003379	83.24	gold quality
deltoid	UBERON:0001476	83.00	silver quality
smooth muscle tissue	UBERON:0001135	82.90	gold quality
adipose tissue	UBERON:0001013	82.56	gold quality
gastrocnemius	UBERON:0001388	82.52	gold quality
cauda epididymis	UBERON:0004360	82.52	gold quality
mucosa of stomach	UBERON:0001199	82.49	gold quality
adipose tissue of abdominal region	UBERON:0007808	82.47	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.57
E-GEOD-110499	no	547.92
E-GEOD-99795	no	45.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

43 targeting PRXL2C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-130B-5P	99.83	68.50	1888
HSA-MIR-4420	99.82	70.08	1624
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-181B-2-3P	99.81	70.06	1646
HSA-MIR-181B-3P	99.81	70.06	1646
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-370-5P	99.78	66.81	706
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-549A-3P	99.54	68.17	825
HSA-MIR-5689	99.50	71.26	1154
HSA-MIR-653-5P	99.46	67.35	1300
HSA-MIR-208A-5P	99.42	70.83	1913
HSA-MIR-208B-5P	99.42	70.83	1952
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-4427	99.34	70.33	1854
HSA-MIR-410-3P	99.27	69.98	2457
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-664A-3P	99.22	71.08	2696
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-196A-3P	99.19	67.34	1204
HSA-MIR-421	98.90	67.04	1883
HSA-MIR-6074	98.89	69.64	2187

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	prxl2c	ENSDARG00000075299
mus_musculus	Prxl2c	ENSMUSG00000021482
rattus_norvegicus	Prxl2c	ENSRNOG00000018886

Protein

Protein identifiers

Peroxiredoxin-like 2C — Q7RTV5 (reviewed: Q7RTV5)

Alternative names: AhpC/TSA antioxidant enzyme domain-containing protein 1, Thioredoxin-like protein AAED1

All UniProt accessions (3): Q7RTV5, H0Y5J5, H0Y7F1

UniProt curated annotations — full annotation on UniProt →

Function. May positively regulate ERK1/2 signaling and AKT1 activation leading to HIF1A up-regulation with an increased expression of glycolysis genes and enhanced glycolysis.

Tissue specificity. Expressed in gastric tissues.

Similarity. Belongs to the peroxiredoxin-like PRXL2 family. PRXL2C subfamily.

RefSeq proteins (1): NP_714542* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR032801	PXL2A/B/C	Family
IPR036249	Thioredoxin-like_sf	Homologous_superfamily

Pfam: PF13911

UniProt features (2 total): chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7RTV5-F1	84.68	0.63

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 148 (showing top): GOBP_NUCLEOSIDE_DIPHOSPHATE_METABOLIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_REGULATION_OF_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_TRIPHOSPHATE_METABOLIC_PROCESS

GO Biological Process (2): positive regulation of glycolytic process (GO:0045821), positive regulation of ERK1 and ERK2 cascade (GO:0070374)

GO Molecular Function (0):

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
glycolytic process	1
regulation of glycolytic process	1
positive regulation of purine nucleotide catabolic process	1
positive regulation of carbohydrate metabolic process	1
positive regulation of ATP metabolic process	1
positive regulation of MAPK cascade	1
ERK1 and ERK2 cascade	1
regulation of ERK1 and ERK2 cascade	1

Protein interactions and networks

STRING

306 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRXL2C	ZNF367	Q7RTV3	568
PRXL2C	TMEM267	Q0VDI3	517
PRXL2C	AADACL4	Q5VUY2	488
PRXL2C	AADACL3	Q5VUY0	460
PRXL2C	MRPS27	Q92552	457
PRXL2C	TRIP12	Q14669	456
PRXL2C	AADACL2	Q6P093	453
PRXL2C	FBXL17	Q9UF56	446
PRXL2C	PRXL2A	Q9BRX8	435
PRXL2C	UBOX5	O94941	433
PRXL2C	ZNF510	Q9Y2H8	422
PRXL2C	ZNF169	Q14929	419
PRXL2C	AAGAB	Q6PD74	404
PRXL2C	AAR2	Q9Y312	404
PRXL2C	DCAF12L1	Q5VU92	400

IntAct

5 interactions, top by confidence:

A	B	Type	Score
PICK1	ILVBL	psi-mi:“MI:0914”(association)	0.530
PICK1	ATP6AP2	psi-mi:“MI:0914”(association)	0.530

BioGRID (5): AAED1 (Affinity Capture-MS), AAED1 (Affinity Capture-MS), AAED1 (Affinity Capture-MS), AAED1 (Affinity Capture-MS), AAED1 (Affinity Capture-RNA)

ESM2 similar proteins: A2A825, A6NKP2, A6NNS2, B4F753, D3ZGP9, D3ZRW8, D3ZVU9, O35469, O54783, O55229, O95278, P14893, P22071, P22072, P26149, P27365, P47802, Q15738, Q1M199, Q1RMJ5, Q32L94, Q3UGX3, Q3ZBE9, Q4R4U1, Q4R7R1, Q5IFP1, Q5PPL3, Q5R5F8, Q5ZIW1, Q60555, Q62878, Q6P4H8, Q7RTV5, Q8CHS7, Q8CIW5, Q8N9F0, Q8WUS8, Q91XQ2, Q923S8, Q96RR1

Diamond homologs: Q148E0, Q7RTV5, Q8AV19, Q9D1A0, Q9ZUU2, A9CQL8, B5X9L9, Q58CY6, Q5R7S9, Q6NV24, Q8TBF2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	27
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

708 predictions. Top by Δscore:

Variant	Effect	Δscore
9:96651387:TACCT:T	donor_loss	1.0000
9:96651388:A:AC	donor_gain	1.0000
9:96651388:A:T	donor_loss	1.0000
9:96651389:C:CC	donor_gain	1.0000
9:96651491:AAAGG:A	acceptor_gain	1.0000
9:96651492:AAGG:A	acceptor_gain	1.0000
9:96651492:AAGGC:A	acceptor_gain	1.0000
9:96651493:AGG:A	acceptor_gain	1.0000
9:96651493:AGGCT:A	acceptor_gain	1.0000
9:96651494:GG:G	acceptor_gain	1.0000
9:96651494:GGCT:G	acceptor_gain	1.0000
9:96651495:GCT:G	acceptor_gain	1.0000
9:96651496:C:CC	acceptor_gain	1.0000
9:96651714:T:C	acceptor_gain	1.0000
9:96651714:T:TC	acceptor_gain	1.0000
9:96654703:A:AC	donor_gain	1.0000
9:96654704:C:CT	donor_gain	1.0000
9:96654770:AATG:A	acceptor_gain	1.0000
9:96654771:ATG:A	acceptor_gain	1.0000
9:96654771:ATGC:A	acceptor_loss	1.0000
9:96654772:TG:T	acceptor_gain	1.0000
9:96654773:GC:G	acceptor_loss	1.0000
9:96654774:C:CA	acceptor_loss	1.0000
9:96654774:C:CC	acceptor_gain	1.0000
9:96654782:C:CT	acceptor_gain	1.0000
9:96654782:C:T	acceptor_gain	1.0000
9:96654783:A:T	acceptor_gain	1.0000
9:96655064:C:A	donor_gain	1.0000
9:96651407:TC:T	donor_gain	0.9900
9:96651496:CT:C	acceptor_gain	0.9900

AlphaMissense

1454 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:96651490:A:C	F107L	0.993
9:96651490:A:T	F107L	0.993
9:96651492:A:G	F107L	0.993
9:96651687:A:T	I96N	0.992
9:96651684:C:T	G97E	0.991
9:96651690:A:T	V95E	0.991
9:96654768:G:C	F66L	0.991
9:96654768:G:T	F66L	0.991
9:96654770:A:G	F66L	0.991
9:96651455:A:T	V119D	0.990
9:96651491:A:C	F107C	0.990
9:96654733:A:G	L78P	0.990
9:96645907:A:G	L180P	0.989
9:96651491:A:G	F107S	0.989
9:96651459:A:C	Y118D	0.988
9:96641859:T:A	D194V	0.987
9:96645975:G:C	S157R	0.987
9:96645975:G:T	S157R	0.987
9:96645977:T:G	S157R	0.987
9:96654764:A:G	C68R	0.987
9:96645904:A:T	I181N	0.986
9:96641832:A:T	I203N	0.985
9:96645913:C:T	G178E	0.985
9:96645921:C:A	Q175H	0.985
9:96645921:C:G	Q175H	0.985
9:96651685:C:G	G97R	0.985
9:96651685:C:T	G97R	0.985
9:96651452:T:C	D120G	0.984
9:96654750:C:A	K72N	0.984
9:96654750:C:G	K72N	0.984

dbSNP variants (sampled 300 via entrez): RS1000010551 (9:96649834 C>G), RS1000035773 (9:96640725 G>A,T), RS1000362731 (9:96654834 A>C), RS1000691767 (9:96643505 C>G), RS1000983037 (9:96642971 A>T), RS1001021112 (9:96648283 T>C), RS1001135002 (9:96648547 A>T), RS1001223419 (9:96650383 C>G), RS1001250239 (9:96654878 G>A,C), RS1001269637 (9:96642711 A>G), RS1001291415 (9:96639399 G>A,T), RS1001405583 (9:96639186 C>G,T), RS1001406475 (9:96644290 G>A), RS1001648282 (9:96653192 A>C), RS1001648663 (9:96645385 T>C)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression	5
Nickel	increases expression	3
Tetrachlorodibenzodioxin	increases expression	2
Cyclosporine	increases expression	2
FR900359	decreases phosphorylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
coumarin	increases phosphorylation	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
(+)-JQ1 compound	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Air Pollutants, Occupational	increases expression	1
Dexamethasone	increases expression	1
Dimethyl Sulfoxide	increases expression	1
Estradiol	increases expression	1
Quercetin	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Aflatoxin B1	increases expression	1
Sodium Selenite	decreases expression	1
Particulate Matter	increases abundance, decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.